4//SEC Filing
Farid Adrienne 4
Accession 0001062993-24-006058
CIK 0001850119other
Filed
Mar 7, 7:00 PM ET
Accepted
Mar 8, 6:29 PM ET
Size
13.9 KB
Accession
0001062993-24-006058
Insider Transaction Report
Form 4
Farid Adrienne
Chief Operations Officer
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-03-06−30,684→ 191,486 totalExercise: $1.03Exp: 2029-07-17→ Common Stock (30,684 underlying) - Sale
Common Stock
2024-03-07$5.14/sh−22,831$117,342→ 114,149 total - Exercise/Conversion
Stock Option (right to buy)
2024-03-07−22,831→ 168,655 totalExercise: $1.03Exp: 2029-07-17→ Common Stock (22,831 underlying) - Exercise/Conversion
Common Stock
2024-03-07$1.03/sh+22,831$23,516→ 136,980 total - Exercise/Conversion
Common Stock
2024-03-06$1.03/sh+30,684$31,605→ 144,833 total - Sale
Common Stock
2024-03-06$4.96/sh−30,684$152,340→ 114,149 total
Footnotes (4)
- [F1]The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.87 to $5.48, inclusive.
- [F4]The option is fully vested and exercisable.
Issuer
Century Therapeutics, Inc.
CIK 0001850119
Entity typeother
Related Parties
1- filerCIK 0001867310
Filing Metadata
- Form type
- 4
- Filed
- Mar 7, 7:00 PM ET
- Accepted
- Mar 8, 6:29 PM ET
- Size
- 13.9 KB